New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
10:17 EDTTSN, WYNN, WU, STJ, BEN, VLO, PRGO, MCHP, UCTT, MJN, BBRY, YHOO, SRE, TXN, TKR, MXWLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: BlackBerry (BBRY) upgraded to Outperform from Market Perform at Bernstein... Franklin Resources (BEN) upgraded to Outperform from Market Perform at Keefe Bruyette... Maxwell (MXWL) upgraded to Overweight from Neutral at Piper Jaffray... Mead Johnson (MJN) upgraded to Conviction Buy from Neutral at Goldman... St. Jude Medical (STJ) upgraded to Outperform from Neutral at Credit Suisse... Timken (TKR) upgraded to Buy from Neutral at BofA/Merrill... Ultra Clean (UCTT) upgraded to Buy from Hold at Needham... Western Union (WU) upgraded to Buy from Hold at Deutsche Bank... Texas Instruments (TXN) upgraded to Buy from Neutral at ISI Group,,, Microchip (MCHP) upgraded to Buy from Neutral at ISI Group... Wynn Resorts (WYNN) upgraded to Buy from Neutral at ISI Group... Sempra Energy (SRE) upgraded to Overweight from Neutral at JPMorgan... Perrigo (PRGO) upgraded to Overweight from Equal Weight at Morgan Stanley... Tyson Foods (TSN) upgraded to Buy from Underperform at CLSA... Yahoo! (YHOO) upgraded to Buy from Hold at Stifel Nicolaus... Valero Energy (VLO) upgraded to Neutral from Underperform at Macquarie.
News For BBRY;BEN;MXWL;MJN;STJ;TKR;UCTT;WU;TXN;MCHP;WYNN;SRE;PRGO;TSN;YHOO;VLO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
April 22, 2015
09:56 EDTPRGOMylan planning firmer offer for Perrigo, CNBC's Faber reports
Mylan (MYL) is planning to announce a firmer takeover offer for Perrigo (PRGO) that will include financing commitments and ticking fees, CNBC's David Faber reports, citing people familiar with the matter. It is unclear if the offer will include a higher buyout price of $205 per share, Faber added.
09:44 EDTPRGOSources: Mylan planning new offer for Perrigo, CNBC's Faber says
Subscribe for More Information
09:01 EDTYHOOYahoo launches new video ad formats for advertisers and developers
Subscribe for More Information
08:49 EDTSTJSt. Jude Medical sees FY16 a 'strong year' for neuromodulation segment
Subscribe for More Information
08:43 EDTPRGOHostile bids carry low success rates, says Leerink
Subscribe for More Information
08:42 EDTPRGOMylan likely to seek higher offer from Teva, says Bernstein
after Teva (TEVA) offered to buy Mylan (MYL) for $82 per share, Bernstein expects Mylan to seek an offer closer to $90. The firm also expects Mylan to seek shared management and perhaps some protection for its employees. Bernstein expects Teva to attempt to convince Mylan shareholders of the merits of its offer and Mylan to attempt to convince Perrigo (PRGO) shareholders of the merits of its offer and its own shareholders of the risks associated with the Teva deal. Bernstein keeps Outperform ratings on Teva and Mylan.
08:31 EDTPRGOTeva files for Hart Scott Rodino notification regarding proposed Mylan purchase
Teva Pharmaceutical Industries (TEVA) announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. Teva’s proposal for Mylan implies a total equity value of approximately $43 billion and an enterprise value of approximately $50 billion. The Teva Board and management team are committed to consummating a transaction as soon as possible. The acquisition proposal would provide Teva stockholders with very attractive strategic and financial benefits and Mylan stockholders with a substantial premium and immediate value for their shares, as well as the opportunity to participate in the significant upside potential of the combined company – one that would transform the global generics space and leverage it to hold a unique leadership position in the pharmaceutical industry. Teva has carefully studied the regulatory aspects of a combination of Teva and Mylan, in conjunction with its advisors. Teva is confident that it would be able to structure a transaction that would not contain material impediments to closing and that it can determine and promptly implement divestitures, as necessary, to gain regulatory clearances. Teva intends to work cooperatively with antitrust authorities and expects that the proposed transaction can be completed by year-end 2015. Teva’s proposal provides Mylan stockholders with a more attractive alternative to Mylan’s proposed acquisition of Perrigo Company plc (PRGO), as announced on April 8, 2015, as well as to Mylan on a standalone basis. Teva’s proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, which is the last day of trading prior to Mylan’s press release regarding its unsolicited proposal for Perrigo, and a 48.3% premium to the unaffected stock price of Mylan on March 10, 2015, which is the last day of trading prior to widespread speculation of a transaction between Teva and Mylan. Barclays and Greenhill & Co. are serving as financial advisors to Teva. Kirkland & Ellis LLP and Tulchinsky Stern Marciano Cohen Levitski & Co are serving as legal counsel to Teva, with De Brauw Blackstone Westbroek N.V. and Loyens & Loeff N.V. acting as legal advisors in the Netherlands.
08:30 EDTSTJSt. Jude Medical sees FY15 CRM constant currency sales down 2% to flat with FY14
Sees FY15 AF product sales growth of 12%-14%. Backs cardiovascular product sales growth view of 6%-8%. Sees neuromodulation products sales growth 13%-15%. Sees acquisition of spinal modulation reducing FY15 EPS by about 5c and accretive to FY16 EPS. Guidance provided during Q1 earnings conference call.
08:21 EDTTXNTexas Instruments April weekly volatility elevated into Q1 and outlook
Subscribe for More Information
07:28 EDTTSNMexico halts imports of poultry products from Iowa due to bird flu, Reuters says
Subscribe for More Information
07:27 EDTPRGOPiper sees more sense in Teva buying Perrigo than Mylan
Piper Jaffray says that while a potential acquisition of Mylan (MYL) by Teva (TEVA) would bring major cost synergies and meaningful earnings accretion, it would not significantly improve the limited visibility on long-term top-line and earnings growth for Teva. Piper sees more strategic sense in Teva acquiring Perrigo (PRGO). Such a deal would drive multiple expansion for Teva since Perrigo's Consumer Health and Nutritionals businesses can offer a "much higher level of visibility on robust long-term earnings growth" than what Mylan can offer Teva, Piper tells investors today. The firm reiterates a Neutral rating on shares of Teva.
07:18 EDTSTJSt. Jude Medical sees Q2 adjusted EPS 99c-$1.01, consensus 99c
For the second quarter, St. Jude Medical expects revenue to grow in the range of 4%-5% on a constant currency basis compared to the second quarter of 2014 with currency negatively impacting second quarter revenue by approximately $125M-$135M. Revenue consensus is $1.4B.
07:18 EDTSTJSt. Jude Medical sees FY15 adjusted EPS $3.92-$3.97, consensus $3.95
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q1 total CRM sales $643M, down 6% y/y
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q1 adjusted EPS 93c, consensus 91c
Reports Q1 revenue $1.35B, consensus $1.32B.
07:14 EDTPRGOTeva Mylan deal more likely to get done than Mylan Perrigo deal,says Wells Fargo
Subscribe for More Information
07:00 EDTPRGOPerrigo price target raised to $203 from $187 at Jefferies
Jefferies raised its price target for Perrigo (PRGO) to $203 after the company rejected Mylan's (MYL) takeover bid of $205 per share. The firm believes Perrigo "left the door wide open" for a higher, more definitive bid. It sees a 40% chance of either Mylan or another suitor acquiring Perrigo. The firm keeps a Buy rating on the stock.
06:32 EDTYHOOYahoo price target lowered to $48 from $56 at Barclays
Subscribe for More Information
06:31 EDTPRGOMylan likely to improve offer for Perrigo, says Citigroup
Citigroup believes Mylan's (MYL) board will likely reject Teva's (TEVA) initial takeover offer of $82 per share and present an improved proposal to acquire Perrigo (PRGO). Citi continues see a potential Teva-Mylan combination as more value accretive for Mylan shareholders than a potential Mylan-Perrigo combination. It keeps a Neutral rating on Mylan.
06:08 EDTYHOOYahoo price target lowered to $54 from $60 at Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use